Manual de Cuidados Paliativos ANCP
340 pág.

Manual de Cuidados Paliativos ANCP


DisciplinaLivros24.006 materiais99.596 seguidores
Pré-visualização50 páginas
undernourished adolescents and young adults. Am J Clin Nutr, v. 55, n. \ufffd, p. 1051-\ufffd0, 1992.
14. DAVIS, M. P.; DICKERSON, D. Cachexia and anorexia: cancer\u2019s covert killer. Support Care Cancer, v. 8, n. 
3, p. 180-\ufffd, 2000.
15. DAVIS, M. P. et al. Management of symptoms associated with advanced cancer: olanzapine and 
mirtazapine. A World Health Organization project. Expert Rev Anticancer Ther, v. 2, n. 4, p. 3\ufffd5-\ufffd\ufffd, 2002.
1\ufffd. DEANS, D. A. et al. Clinical prognostic scoring system to aid decision-making in gastro-oesophageal 
cancer. Br J Surg, v. 94, n. 12, p. 1501-8, 200\ufffd.
1\ufffd. DEL FABBRO, E. Comunicação pessoal 2009.
1\ufffd0
Manual de Cuidados Paliativos da ANCP
18. DELLA CUNA, G. R.; PELLEGRINI, A.; PIAZZI, M. Effect of methylprednisolone sodium succinate on quality of 
life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal 
Cancer Study Group. Eur J Cancer Clin Oncol, v. 25, n. 12, p. 181\ufffd-21, 1989.
19. DEWEY, A. et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of 
cancer cachexia. Cochrane Database Syst Rev, n. 1, CD00459\ufffd, 200\ufffd.
20. EVANS, W. J. et al. Cachexia: a new definition. Clin Nutr, v. 2\ufffd, n. \ufffd, p. \ufffd93-9, 2008.
21. FEARON, K. Comunicação pessoal, 2009.
22. FEARON, K. C.; VOSS, A. C.; HUSTEAD, D. S. Definition of cancer cachexia: effect of weight loss, reduced 
food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr,v. 83, n. \ufffd, p.1345-
50, 200\ufffd.
23. FOULADIUN, M. et al. Daily physical-rest activities in relation to nutritional state, metabolism, and quality 
of life in cancer patients with progressive cachexia. Clin Cancer Res, v. 13, n. 21, p. \ufffd3\ufffd9-85, 200\ufffd.
24. GELATO, M.; MCNURLAN, M.; FREEDLAND, E. Role of recombinant human growth hormone in HIV-
associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther, v. 29, n. 11, p. 22\ufffd9-
88, 200\ufffd.
25. GORDON, J. N. et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled 
trial. Gut, v. 54, n. 4, p. 540-5, 2005.
2\ufffd. HINSLEY, R.; HUGHES, R. The reflections you get: an exploration of body image and cachexia. Int J Palliat 
Nurs, v. 13, n. 2, p. 84-9, 200\ufffd.
2\ufffd. JATOI, A. et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients 
with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of 
Canada collaborative effort. J Clin Oncol, v. 22, n. 12, p. 24\ufffd9-\ufffd\ufffd, 2004.
28. KALANTAR-ZADEH, K.; FOUQUE, D.; KOPPLE, J. D. Outcome research, nutrition, and reverse epidemiology 
in maintenance dialysis patients. J Ren Nutr, v. 14, n. 2, p. \ufffd4-\ufffd1, 2004.
29. KALANTAR-ZADEH, K. et al. Comparing outcome predictability of markers of malnutrition-inflammation 
complex syndrome in haemodialysis patients. Nephrol Dial Transplant, v. 19, n. \ufffd, p. 150\ufffd-19, 2004.
30. KALANTAR-ZADEH, K. et al. Associations of body fat and its changes over time with quality of life and 
prospective mortality in hemodialysis patients. Am J Clin Nutr, v. 83, n. 2, p. 202-10, 200\ufffd.
31. KAPLAN, G. et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses, 
v. 1\ufffd, n. 14, p. 1345-55, 2000.
32. KATSURA, H.; YAMADA, K.; KIDA, K. Both generic and disease specific health-related quality of life are 
deteriorated in patients with underweight COPD. Respir Med, v. 99, n. 5, p. \ufffd24-30, 2005.
33. KLEIN, S.; KORETZ, R. L. Nutrition support in patients with cancer: what do the data really show? Nutr 
Clin Pract, v. 9, n. 3, p. 91-100, 1994.
34. KOEHLER, F. et al. Anorexia in chronic obstructive pulmonary disease: association to cachexia and 
hormonal derangement. Int J Cardiol, v. 119, n. 1, p. 83-9, 200\ufffd.
35. LISSONI, P. Is there a role for melatonin in supportive care? Support Care Cancer, v. 10, n. 2, p. 110-\ufffd, 2002.
3\ufffd. LOHMAN, T. G. Skinfolds and body density and their relation to body fatness: a review. Hum Biol, v. 53, 
n. 2, p. 181-225, 1981.
3\ufffd. LOPRINZI, C. L. et al. Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with 
cancer anorexia and/or cachexia. Oncology, v. 51, suppl. 1, p. 2-\ufffd, 1994.
38. LOPRINZI, C. L. et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with 
cancer anorexia and/or cachexia. J Clin Oncol, v. 11, n. 4, p. \ufffd\ufffd2-\ufffd, 1993.
39. MA, G.; ALEXANDER, H. Prevalence and pathophysiology of cancer cachexia. In: BRUERA, E.; PORTENOY, 
R. K. (eds.). Topics in palliative care. New York: Oxford University Press, 1998. p. 91-129.
40. MAK, R. H.; CHEUNG, W. Cachexia in chronic kidney disease: role of inflammation and neuropeptide 
signaling. Curr Opin Nephrol Hypertens, v. 1\ufffd, n. 1, p. 2\ufffd-31, 200\ufffd.
41. MCCLEMENT, S. Cancer anorexia-cachexia syndrome: psychological effect on the patient and family. J 
Wound Ostomy Continence Nurs, v. 32, n. 4, p. 2\ufffd4-8, 2005.
42. MCGEER, A. J.; DETSKY, A. S.; O\u2019ROURKE, K. Parenteral nutrition in cancer patients undergoing 
chemotherapy: a meta-analysis. Nutrition, v. \ufffd, n. 3, p. 233-40, 1990.
43. MOERTEL, C. G. et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer, v. 33, n. \ufffd), 
p. 1\ufffd0\ufffd-9, 19\ufffd4.
44. MULLIGAN, K.; SCHAMBELAN, M. Anabolic treatment with GH, IGF-I or anabolic steroids in patients with 
HIV-associated wasting. Int J Cardiol, v. 85, n. 1, p. 151-9, 2002.
1\ufffd1
45. NAGAYA, N. et al. Treatment of cachexia with ghrelin in patients with COPD. Chest, v. 128, n. 3, p. 118\ufffd-
93, 2005.
4\ufffd. NAGAYA, N.; KOJIMA, M.; KANGAWA, K. Ghrelin, a novel growth hormone-releasing peptide, in the 
treatment of cardiopulmonary-associated cachexia. Intern Med, v. 45, n. 3, p. 12\ufffd-34, 200\ufffd.
4\ufffd. NAHLEN, B. L. et al. HIV wasting syndrome in the United States. AIDS, v. \ufffd, n. 2, p. 183-8, 1993.
48. ORR, R.; FIATARONE SINGH, M. The anabolic androgenic steroid oxandrolone in the treatment of wasting 
and catabolic disorders: review of efficacy and safety. Drugs, v. \ufffd4, n. \ufffd, p. \ufffd25-50, 2004.
49. OVESEN, L. et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and 
quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol, 11, 
n. 10, p. 2043-9, 1993.
50. PERSSON, C. et al. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal 
cancer: a randomized pilot study. Nutrition, v. 21, n. 2, p. 1\ufffd0-8, 2005.
51. PORTENOY, R. K.; ITRI, L. M. Cancer-related fatigue: guidelines for evaluation and management. 
Oncologist, v. 4, n. 1, p. 1-10, 1999.
52. SCHOLS, A. M. et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin 
Nutr, v. 82, n. 1, p. 53-9, 2005.
53. SCHOLS, A. M. et al. Physiologic effects of nutritional support and anabolic steroids in patients with 
chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med, v. 
152, n. 4 Pt 1, p. 12\ufffd8-\ufffd4, 1995.
54. SEIDELL, J. C.; BAKKER, C. J.; VAN DER KOOY, K. Imaging techniques for measuring adipose-tissue 
distribution: a comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr, v. 
51, n. \ufffd, p. 953-\ufffd, 1990.
55. SHARPE, M. C. et al. A report \u2013 chronic fatigue syndrome: guidelines for research. J R Soc Med, v. 84, n. 
2, p. 118-21, 1991.
5\ufffd. SIMONS, J. P. et al. Effects of medroxyprogesterone acetate on food intake, body composition, and resting 
energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled 
trial. Cancer, v. 82, n. 3, p. 553-\ufffd0, 1998.
5\ufffd. STRASSER, F. et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related 
anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer, v. 98, 
n. 2, p. 300-8, 2008.
58. STRASSER,